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ABSTRACT
Background. Intraperitoneal chemotherapy is limited by
tissue penetration. Pressurized intraperitoneal aerosol
chemotherapy (PIPAC) has been shown to improve drug
uptake by utilizing the physical properties of gas and
pressure. This study investigated the effect of adding
electrostatic precipitation to further enhance the pharma-
cologic properties of this technique.
Methods. A comparative study was performed using an
in vivo porcine model. There were 3 cases in each group,
PIPAC and electrostatic precipitation pressurized
intraperitoneal aerosol chemotherapy (ePIPAC), plus 1
negative control comparing intraperitoneal distribution and
tissue uptake of 2 tracer substances (toluidine blue and
DT01). Tracer uptake was determined by measuring DT01
in tissue and peritoneal fluid at the end of each procedure.
Results. Electrostatic precipitation of the aerosol was
technically feasible in all ePIPAC animals. The aerosol was
cleared completely from the visual field within 15 s in the
ePIPAC group versus 30 min in the PIPAC group. The
peritoneal surface was homogeneously stained in both
groups. After 30 min, 1.5 % remaining DT01 was mea-
sured in samples of ePIPAC-treated peritoneal fluid versus
15 % in PIPAC animals (p = 0.01). Tissue concentration
was increased after ePIPAC versus PIPAC (p = 0.06).
Conclusions. ePIPAC is technically feasible and improves
tissue uptake of 2 tracer substances compared to PIPAC by
up to tenfold. Intraperitoneal distribution was homoge-
neous in both groups. ePIPAC has the potential to allow
more efficient drug uptake, further dose reduction, a sig-
nificant shortening of the time required for PIPAC
application, and improved health and safety measures.
Research on tumor nonresponse to therapy has focused
on the molecular mechanisms of chemoresistance, with
drug distribution being comparatively neglected.1 For
cytostatic drugs to be successful, they must fully penetrate
the tissue of interest, reaching within all the cancer cells at
a concentration sufficient to exert a therapeutic effect.
Intraperitoneal tumor dissemination and metastasis is
common in several forms of abdominal cancer.2 Numerous
studies have investigated the potential role of intraperitoneal
drug delivery as an adjunct to systemic chemotherapy in this
situation.3 The rationale of intraperitoneal administration is
to improve the therapeutic index by increasing the exposure
of cancer cells within the peritoneal cavity to the drug while
minimizing toxic effects to other organs. Prior studies have
documented the limitations of intraperitoneal chemotherapy
including the limited direct penetration of drugs into the
tumor tissue and the unequal drug distribution throughout the
peritoneal cavity.4
Pressurized intraperitoneal aerosol chemotherapy
(PIPAC) is an innovative drug delivery system that takes
advantage of the physical properties of the combination of
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gas and pressure in order to overcome these pharmacologic
limitations.5 There is substantial in vitro, in vivo, and
ex vivo evidence as well as evidence in human patients that
PIPAC has superior pharmacologic properties.6–9 Because
the therapeutic ratio between local and systemic drug
concentration is increased by PIPAC, enhanced local effi-
cacy together with low systemic toxicity was expected and
has been demonstrated clinically.10 Retrospective analysis
of the patient cohorts in ovarian gastric and colorectal
cancer have shown encouraging results of repeated PIPAC
in the palliative situation.11–13 A prospective phase 2 trial
with low-dose doxorubicin and cisplatin in recurrent, pla-
tin-resistant ovarian cancer applied as a pressurized aerosol
showed a clinical benefit rate of 62 % and an objective
histologic regression rate of 76 %, coupled with a low
incidence of severe adverse events (15 % Common Ter-
minology Criteria for Adverse Events [CTCAE] grade 3,
no CTCAE grades 4 or 5).14,15 So far, the role of PIPAC in
combination with advanced cytoreductive surgery has not
been determined.
We hypothesized that electrostatic precipitation may
further enhance the pharmacologic properties of PIPAC as
so-called electrostatic precipitation pressurized intraperi-
toneal aerosol chemotherapy (ePIPAC). For electrostatic
precipitation, we used a commercially available, CE-certi-
fied technology developed for clearing surgical smoke from
the operative field of view during laparoscopy (Ultravision,
Alesi Surgical Ltd., UK). The performance and safety of
Ultravision has been demonstrated in bench studies, pre-
clinical testing, and clinical testing, including a clinical
study on 30 patients undergoing laparoscopic cholecystec-
tomy.16,17 In particular, no adverse events such as cardiac
arrhythmia, modification of ECG, bowel perforations, or
skin burning were reported.
The aims of this study were to assess the technical
feasibility of ePIPAC, to compare the homogeneity of
intraperitoneal distribution between PIPAC and ePIPAC,




This was an exploratory experimental in vivo study in a
large animal model comparing the effect of ePIPAC (3
animals) versus PIPAC (3 animals) versus 1 control animal
(ePIPAC, no stain).
Animal Model
The experiment was performed in compliance with the
German Animal Protection Law (TierSchG 2006) and was
authorized by the competent authority, State of Thuringia.
ARRIVE guidelines were implemented. Seven German
nonsyngeneic landrace pigs (5 females, 2 males) weighing
31.5 ± 4.5 kg were operated on by qualified surgeons
under the supervision of a veterinarian. The sample size
was determined in order to obtain experimental results in
triplicate plus a negative control. Animals were randomly
assigned to the experimental groups. Procedures were
performed under general anesthesia adhering to strict pro-
tocols. The animals were euthanized under narcosis at the
end of the procedure and immediately necropsied. The
primary outcome measure was DT01 concentration in tis-
sue and peritoneal fluid at the end of the procedures
(quantitative measurement). Secondary outcomes were the
homogeneity of blue staining within the peritoneal cavity
(qualitative measurement) and the toluidine blue concen-
tration in the peritoneal fluid at the end of the procedure
(semiquantitative measurement).
Staining Substances
DT01 are noncoding small DNA fragments designed to
bait and hijack the enzyme complexes that repair DNA
double-strand breaks, diverting them away from their pri-
mary objective, the double-strand breaks on
chromosomes.15,18 DT01 administration with PIPAC has
previously been validated.8 In this study, 30 mg toluidine
blue and 6 mg Cy5-labeled DT01 were diluted in 1000 ml
NaCl 0.9 % solution. A volume of 150 ml solution was
administered via an aerosolizer (Capnopen, Capnomed
GmbH, Germany) to each animal (n = 6). The negative
control animal received 150 ml NaCl 0.9 %.
Experimental Protocol
PIPAC was applied as described previously.9 After
insufflation of a 12 mm Hg capnoperitoneum with a Veress
needle, 2 balloon safety trocars (Kii 5 and 12 mm; Applied
Medical, Germany) were inserted into the abdominal wall.
The Capnopen was connected to an intravenous high-
pressure injector (Arterion 7; Medrad, Germany) and
inserted into the abdomen. The pressurized aerosol was
applied via aerosolizer and injector. Flow rate was 30 ml/
min, and maximal upstream pressure was 200 psi. The
therapeutic capnoperitoneum was maintained for 30 min.
The aerosol was exsufflated and the trocars removed.
Identical conditions were used for the ePIPAC subjects
(n = 3), with the additional use of the Ultravision tech-
nology. The system was activated at the point of
completion of aerosol generation and the electric current
was maintained for 30 min. This negative control animal
received NaCl 0.9 % through ePIPAC under the above
conditions.
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Electrostatic Precipitation
The Ultravision system integrates the following com-
ponents: a generator unit (voltage 7500–9500 V, current
B10 lA), an active cable terminating in an atraumatic
stainless steel brush electrode (Ionwand) that is responsible
for the electrostatic charging of aerosol particles, and a
return electrode with a solid patient return plate (Fig. 1).
The Ionwand emits a stream of electrons, resulting in the
creation of negative gas ions. The gas ions collide with
particulate matter, passing on the negative charge. The
return electrode confers a weak positive charge on the
subject, which results in the electrostatic attraction of the
negatively charged aerosol particles to the tissue surfaces
of the contained space—that is, the peritoneum.
Analysis
Toluidine blue distribution was assessed qualitatively as
described previously.7 Immediately after the procedure,
peritoneum was sampled via biopsy; peritoneal fluid was
sampled, and droplets were distributed onto filter paper to
visualize the intensity of the blue stain. The tissue and
peritoneal fluid samples were snap-frozen in liquid nitro-
gen and processed at the Institut Curie/Orsay for blinded
analysis. The quantitation of DT01 in the peritoneal fluid
was performed by a hybridization enzyme-linked
immunosorbent assay (ELISA) using a biotin-conjugated
capture oligonucleotide probe (300 ll) and a digoxigenin-
conjugated detection probe (300 ll), with sequences
complementary to the DT01 sequence (Exiqon, USA) in
96-well plates. Then samples were incubated with an anti-
digoxigenin horseradish peroxidase–conjugated antibody
(1:10,000; Roche, USA), and detection was performed by
the addition of 3,30,5,50-tetramethylbenzidine substrate
(100 ll). Absorbance was measured at 450 and 560 nm,
and quantity of DT01 was calculated from calibration
standards over a working range of 25–1000 ng/ml using a
4-parameter logistic curve. Because the ELISA failed to
produce reliable quantification in tissues, we used fluores-
cent quantification, a reliable technique for assessing
molecule distribution.19 Peritoneal tissue samples were
defrosted, then crushed in phosphate-buffered saline–
ethylenediaminetetraacetic acid. Fifty microliters of each
extract was formed into aliquots in a 96-well plate, and
fluorescence was measured with a Typhoon scanner (GE
Healthcare, USA). The quantity of DT01 was calculated
from a standard curve performed using peritoneal extract
from untreated groups, with Cy5-labeled DT01 concen-
trations ranging from 0 to 1 lg/ml.
Statistics
Size sample was determined and limited by the decision
of the regulatory authority: experiments in triplicate













FIG. 1 Principle of electrostatic precipitation ePIPAC. a Technical
setting for ePIPAC, including high-pressure injector containing
therapeutic solution micropump generating pressurized intraperi-
toneal aerosol, brush electrode for electrostatic loading of therapeutic
aerosol, and return electrode (solid plate). b Intraoperative view of
abdomen showing micropump producing aerosol and electrode
actively loading this aerosol with electrostatic charges, leading to
precipitation of aerosol particles
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statistics including mean and standard deviation are pro-
vided. The null hypothesis was that DT01 concentration
was equal in the peritoneal fluid and in peritoneal biopsy
samples of PIPAC and ePIPAC animals. In spite of the
small sample size, an exploratory comparative analysis was
performed by a nonparametric test (Kruskal–Wallis test for
independent samples). A p value of\0.05 was considered
significant.
RESULTS
There were no technical difficulties or intraoperative
complications in any of the cases. In both the PIPAC and
ePIPAC groups, rapid nebulization of the toluidine blue
solution within the tightly closed abdomen was observed.
Videoscopic control showed immediate staining of the
complete abdominal cavity in both PIPAC and ePIPAC
animals, including all exposed peritoneal surfaces. Intra-
abdominal organs were not mobilized.
In the ePIPAC group, electrostatic loading of the saline
aerosol was technically feasible without significant aber-
rant conduction. The maximal allowed current intensity
was not reached in the ePIPAC group, denoted by the
absence of an alarm signal. After activation of the electrode
in the ePIPAC group, the aerosol completely cleared from
the field of view within 15 s, as documented by real-time
videoendoscopy. In contrast, in the PIPAC animals, aerosol
particles remained in suspension until the end of the pro-
cedure (after 30 min of steady state).
At necropsy, macroscopic stain distribution throughout the
entire peritoneal cavity was homogeneous in the PIPAC
group, including the small bowel and anterior abdominal wall
and hidden surfaces such as the inferior aspect of the liver and
the liver hilum. Comparable results were obtained in the
ePIPAC group. In particular, no staining gradient toward or
from the brush electrode was observed in the ePIPAC animals
(Fig. 2). No bowel lesion or perforation was noted.
After 30 min, peritoneal fluid still demonstrated the blue
staining in the PIPAC group (Supplementary material 1,
arrows), whereas it was greatly reduced in the ePIPAC
group. This qualitative impression was confirmed by the
absence of color on filter paper with peritoneal fluid after
ePIPAC. In contrast, blue staining of the peritoneal fluid
was still present after PIPAC.
The concentration of Cy5-labeled DT01 in the peri-
toneal fluid was lower after ePIPAC compared to PIPAC
(Fig. 3a), confirming the results obtained from the tolu-
idine blue assessment. The mean initial DT01
concentration in the aerosolized solution was
8.93 ± 0.72 lg/ml. After PIPAC, this concentration
FIG. 2 Adequacy of toluidine blue distribution. Autopsy findings in
PIPAC (a1, a2) and ePIPAC (b1, b2) animals after aerosolization of
low-dose toluidine blue. Staining of serosal surfaces is homogeneous
in both groups. Importantly, inferior aspect of liver, including hilum
and gallbladder, are stained
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diminished to 1.46 ± 0.21 lg/ml, indirectly documenting
a tissue uptake of 83.6 % in this closed system. After
ePIPAC, the concentration further dropped to
0.11 ± 0.02 lg/ml, suggesting an almost complete tissue
uptake of DT01 (98.7 %). The null hypothesis could
therefore be rejected (p = 0.01). Superior DT01 uptake
after ePIPAC versus PIPAC was confirmed by tissue
measurement (Fig. 3b): DT01 concentration in tissue
increased from 0.05 lg/ml (background noise) before
therapy to 0.41 ± 0.17 lg/ml after PIPAC application and
to 0.57 ± 0.20 lg/ml after ePIPAC application (p = 0.06).
DISCUSSION
In this experimental study, we combined 3 physical
principles (electrostatic precipitation, aerosol nature, and
hydrostatic pressure) with the aim of further improving
tissue uptake after intraperitoneal delivery, thus developing
the concept of ePIPAC.
Electrostatic loading of a therapeutic aerosol was tech-
nically feasible in all ePIPAC animals in an environment
highly saturated with saline solution without creating
significant erratic electric currents. The aerosol was cleared
much more quickly in ePIPAC animals compared to
PIPAC animals. No major macroscopic differences were
noted in dye distribution; in particular, there was no optical
tissue staining gradient toward or from the active electrode
in the ePIPAC group. At the end of the procedure, the
peritoneal fluid was colorless in the ePIPAC group while
the blue color was maintained in the PIPAC group, sug-
gesting a more effective clearance of toluidine blue from
the aerosol after electrostatic precipitation. Subsequent
semiquantitative analysis with filter paper confirmed this
clinical impression. Quantitative results obtained with the
second tracer (DT01) demonstrated that transfer of the
tracer from the aqueous solution to tissue surfaces was
improved after ePIPAC compared to PIPAC. After PIPAC,
approximately 1/10 of the DT01 was present within the
peritoneal cavity, while with ePIPAC only about 1/102
remained. DT01 is a much larger molecule than toluidine
blue, and therefore such efficient uptake was not antici-
pated. This superior uptake after ePIPAC was confirmed by
a higher tissue concentration than after PIPAC.
This difference in uptake represents a further improve-
ment in the context of an earlier study in which tissue
concentration of doxorubicin after PIPAC was found to be
up to 200 times higher than reported after hyperthermic
intraperitoneal chemotherapy (HIPEC), with only 10 % of
the dose.9
Application of intraperitoneal chemotherapy with ePI-
PAC may have several potential advantages over existing
techniques:
– First, if it can be shown that increased deposition
efficiency translates to an increased tissue uptake, then
it may increase drug uptake into tumor nodes and
therefore achieve cytotoxic dose in larger nodules. This
could in turn reduce the need for aggressive cytore-
ductive surgery and allow therapy of diffuse small
bowel involvement, a contraindication for cytoreduc-
tive surgery and HIPEC.20
– Second, it may allow a further reduction of the dose
needed to be effective. In ovarian and gastric cancer,
PIPAC has been shown to be effective with 10 % of the
usual systemic dose of cisplatin and doxorubicin.12,14
In colorectal cancer, PIPAC was effective with 20 % of
the doses generally administered for HIPEC.13 Dose
reduction allows not only a reduction in organ toxicity
and systemic side effects but also a limit to local
toxicity on the bowel and the normal peritoneum.10,14
The clinical significance of this is the possibility to use
PIPAC earlier in the course of the disease as a
secondary prevention of peritoneal metastasis, analo-
gous to HIPEC, and may contribute to a lower
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FIG. 3 a Peritoneal fluid DT01 concentration showing 15 %
remaining concentration after PIPAC compared to initial concentra-
tion in aerosolized solution versus 1.5 % after ePIPAC (p = 0.01).
Whereas PIPAC allows 85 % tissue uptake, ePIPAC achieves another
order of magnitude with 98.5 % absorption. b Tissue DT01 concen-
tration after PIPAC vs. ePIPAC application, confirming superior
uptake after ePIPAC (p = 0.06)
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– Third, ePIPAC may allow a significant reduction of the
time needed for application.
– Finally, it may simplify the occupational safety aspects
of PIPAC by reducing time of potential exposure and
by minimizing any residual drug evacuated at the end
of the procedure.
There are several limitations to this early work. These
data have been obtained in an experimental model and
cannot be extrapolated to human patients without further
validation. This study was not performed in an animal
model of peritoneal metastasis but in healthy pigs because
such a model is not available. Therefore, tracer penetration
into tumor tissue could not be assessed.
It was not possible to apply toxic agents such as cyto-
toxic drugs within the experimental operating room as a
result of the absence of high-flow ventilation. Although
DT01 is a validated marker for determining tissue drug
uptake, the results presented are only valid for the sub-
stances tested.8,26 It is likely that the ability to improve
tissue deposition of drug substances using electrostatic
precipitation will be affected by the physical characteristics
of these molecules. Thus, it is not possible to extrapolate
the clearance of toluidine blue and DT01 to the clearance
of chemotherapy drugs. Additional pharmacologic studies
are required for each drug used for ePIPAC.
CONCLUSIONS
The therapeutic effect of ePIPAC is through a combina-
tion of aerosolization of the drug, applying a pressure across
it and application of an electrostatic gradient. ePIPAC is
technically feasible and improves tissue uptake of 2 tracer
substances compared to PIPAC. ePIPAC has the potential to
allow more efficient drug uptake, to permit further dose
reduction, to significantly shorten the time required for
PIPAC application, and to improve health and safety in the
operating room when undertaking such procedures.
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